COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Long-term Safety and Efficacy Study of SPK-9001 in Individuals With Hemophilia B

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03307980
Recruitment Status : Recruiting
First Posted : October 12, 2017
Last Update Posted : December 4, 2019
Information provided by (Responsible Party):

Brief Summary:
Long-term safety follow-up for subjects with Hemophilia B and previously treated in the C0371005 (formerly SPK-9001-101) protocol

Condition or disease Intervention/treatment Phase
Hemophilia B Biological: SPK-9001 Phase 2

Detailed Description:
Evaluation of the long term level of persistence and potential late or delayed adverse events associated with SPK-9001, assessment of the durability of the transgene expression, and determination of the effects of SPK-9001 on clinical outcomes in individuals who have previously received a single administration of SPK-9001

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: This is a long term follow up (LTFU) study designed to evaluate the overall long term safety, durability of transgene expression, and effect on clinical outcomes of SPK 9001 mediated gene transfer. While safety will be monitored in general, new onset of oncologic, hematologic, neurologic, or auto immune events will be of particular interest. This trial will last for 5 years providing a minimum of 6 years of follow up post vector administration.
Masking: None (Open Label)
Primary Purpose: Treatment
Actual Study Start Date : June 22, 2017
Estimated Primary Completion Date : October 6, 2026
Estimated Study Completion Date : October 6, 2026

Resource links provided by the National Library of Medicine

Intervention Details:
  • Biological: SPK-9001
    Observational long-term safety follow-up study of subjects previously treated in the C0371005 (formerly SPK-9001-101) protocol

Primary Outcome Measures :
  1. SPK-9001-related adverse advents [ Time Frame: up to 5 years ]
    adverse events

Secondary Outcome Measures :
  1. Coagulation Clotting Assay for FIX activity levels [ Time Frame: up to 5 years ]
    Coagulation Clotting assays to assess FIX activity levels (percent of normal)

  2. Annualized (factor FIX) infusion rate [ Time Frame: up to 5 years ]
    AIR (not including those for surgery)

  3. Total factor consumption (IU and volume) [ Time Frame: up to 5 years ]
    total quantity of factor infused annually (not including those for surgery) as recorded on the infusion log

  4. Annualized bleeding rate [ Time Frame: up to 5 years ]
    ABR (not including those for surgery)

  5. Total number of bleeding events [ Time Frame: up to 5 years ]
    (spontaneous and traumatic)

  6. Haem-A-QoL [ Time Frame: up to 5 years ]
    Quality-of-life (QoL) assessment

  7. EQ-5D-5L [ Time Frame: up to 5 years ]
    Quality-of-life (QoL) assessment

  8. Brief Pain Inventory [ Time Frame: up to 5 years ]
    Quality-of-life (QoL) assessment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Genetic males
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
  2. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  3. Subjects who met the C0371005 eligibility criteria, have received a single administration of SPK-9001, and completed the required assessments in the C0371005 clinical study.

Exclusion Criteria:

  1. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
  2. Participation in other studies involving investigational drug(s) within the last 12 weeks prior to study entry, excluding participation in C0371005, and/or during study participation.
  3. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  4. Fertile male subjects who are unwilling or unable to use a condom as outlined in this protocol until 3 consecutive semen samples are negative in the vector shedding analysis after the last dose of investigational product.
  5. Subjects who will not consent for up to 5 years of safety follow-up.
  6. Subjects who are unable or unwilling to comply with the study visits and requirements.
  7. Subjects with any clinically significant medical condition that the Investigator believes would pose as a safety risk or are not capable of performing the endpoints of this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03307980

Layout table for location contacts
Contact: Pfizer Call Center 1-800-718-1021

Layout table for location information
United States, California
UC Davis CTSC Clinical Research Center Recruiting
Sacramento, California, United States, 95817
UC Davis Health Recruiting
Sacramento, California, United States, 95817
UC Davis Investigational Pharmacy Recruiting
Sacramento, California, United States, 95817
United States, Mississippi
Mississippi Center for Advanced Medicine Recruiting
Madison, Mississippi, United States, 39110
United States, New York
Weill Cornell Medicine - New York Presbyterian Hospital Recruiting
New York, New York, United States, 10065
United States, Pennsylvania
The Children's Hospital of Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19104
Australia, New South Wales
Royal Prince Alfred Hospital Recruiting
Camperdown, New South Wales, Australia, 2050
Sponsors and Collaborators
Layout table for investigator information
Study Director: Pfizer Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Pfizer Identifier: NCT03307980    
Other Study ID Numbers: C0371003
SPK-9001-LTFU-101 ( Other Identifier: Alias Study Number )
First Posted: October 12, 2017    Key Record Dates
Last Update Posted: December 4, 2019
Last Verified: December 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at:

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pfizer:
gene therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemophilia A
Hemophilia B
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked